GE HealthCare has unveiled its latest innovation, the MIM Symphony HDR Prostate, aimed at enhancing high dose-rate (HDR) brachytherapy for prostate cancer. This cutting-edge solution leverages MRI scans for precise tumor visualization during live ultrasound procedures, promising improved clinician confidence and patient outcomes.
The MIM Symphony HDR Prostate addresses a critical challenge in HDR brachytherapy: aligning MRI contours with live ultrasound images. Traditionally, clinicians rely on CT or ultrasound for planning these procedures, but incorporating MRI can reduce toxicity to critical structures. The new system corrects MRI orientation and provides MRI guidance, offering clear visibility of the prostate, lesions, and essential structures during treatments.
The solution boasts several key features designed to enhance procedural accuracy. It aids in defining lesions and tracking changes, thereby guiding needle placement even as the prostate moves. The ReSlicer tool corrects orientation differences between MRI supine and ultrasound lithotomy positions. Additionally, the system automatically digitizes needles on CT or ultrasound planning images, conducting needle reviews and free length checks to ensure precision. Dr. Peter Rossi, a prominent radiation oncologist, emphasized MRI's superiority in planning HDR prostate procedures, highlighting the precision and reduced toxicity it offers.
This launch is part of GE HealthCare’s broader strategy to enhance its radiation oncology solutions. Following the acquisition of MIM Software’s portfolio, GE continues to provide comprehensive, vendor-neutral solutions that drive efficiency and optimize care across the radiation oncology spectrum.
Click here to read the original news story.